BIOA-B BioArctic AB (publ)

29.64USD300.60 SEK · STO-1.83%Mkt Cap: 2.63B USDP/E: 254.75

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medic…

Institutional holders11 on file

Key Statistics

Company
Market Cap2.63B USD
Enterprise Value2.49B USD
Revenue (TTM)98.86M USD
Gross Profit191.29M USD
Net Income (TTM)100.81M USD
Revenue/Share1.12 USD
Last Price29.64 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees150
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0010323311
Valuation
P/E (Trailing)254.75
P/E (Forward)103.66
PEG—
EV/EBITDA—
EV/Revenue25.21
P/S26.61
P/B13.23
EPS (TTM)0.12 USD
EPS (Forward)0.29 USD
52W Range
25.7638% of range35.93
52W High35.93 USD
52W Low25.76 USD
Profitability
Gross Margin97.04%
Oper. Margin19.62%
EBITDA Margin0.00%
Profit Margin51.14%
ROE51.97%
ROA39.70%
ROIC—
ROCE66.60%
Growth
Revenue Growth-36.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF141.12M USD
CapEx (TTM)1.01M USD
FCF Margin19.18%
FCF Yield0.72%
Net Debt-187.30M USD
Net Debt/EBITDA—
Net Debt/FCF-9.88
Balance Sheet
Debt/Equity0.02
Current Ratio3.99
Quick Ratio2.97
Book Value/Sh2.24 USD
Cash/Share2.21 USD
Dividends
Fwd Div Rate0.20 USD
Trail. Div Rate0.20 USD
Div. Yield0.65%
5Y Avg Yield—
Payout Ratio173.91%
Ex-Div DateMay 29, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)30.96 USD
Upside (mean)+4.5%
Target Range26.62 USD – 35.60 USD
26.62+4.5% to mean35.60
# Analysts4
Ownership
Shares Out.74.34M
Float54.58M
Insiders42.34%
Institutions31.14%
Technical
SMA 5030.43 (-2.6%)
SMA 20031.21 (-5.0%)
Beta-0.63
S&P 52W Chg12.00%
Avg Vol (30d)98.66K
Avg Vol (10d)84.75K
Technical Indicators
RSI (14)42.5
MACD-0.4631
MACD Signal0.5060
MACD Hist.-0.9691
BB Upper31.64 USD
BB Middle30.61 USD
BB Lower29.58 USD
BB Width6.75%
ATR (14)0.8366 USD
Vol Ratio (20d)0.77x

About BioArctic (STO: BIOA-B)

›

BioArctic (STO: BIOA-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 150 employees.

The shares were at 300.60 SEK on 20 November 2026, up 13.5% over 52 weeks. Its 52-week range is 261.20 SEK to 364.40 SEK: the price is 17.5% below the high and 15.1% above the low.

At a market capitalisation of 26.68B SEK, it trades at 254.7 times trailing earnings and 103.7 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 669% for BIOA-B. It pays a dividend yielding 0.65% (it pays out 174% of its earnings), against a median of 0.95% among the dividend payers in that peer group.

BioArctic reports return on equity of 52.0%, an operating margin of 19.6% and revenue down 36.9% year over year.

It holds more cash than debt, a net cash position of 1.90B SEK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock; their mean price target of 314.00 SEK is 4.5% above the current price. The next earnings report is expected on 25 November 2026.